[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT06898905":3,"trial-entities:NCT06898905":95,"trial-summary:NCT06898905":98},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":25,"primary_purpose":26,"phases":27,"enrollment_info":29,"interventions":32,"primary_outcomes":38,"secondary_outcomes":55,"sex":56,"minimum_age":57,"maximum_age":58,"healthy_volunteers":59,"eligibility_criteria":60,"std_ages":64,"locations":67,"central_contacts":85,"overall_officials":90,"references":93,"see_also_links":94},"NCT06898905","2000038092","Hyperfractionated Dual Equivalent Fractionated Radiation Therapy","Hyperfractionated Dual Equivalent Fractionated (HyDEF) Bridging Radiation Therapy in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Undergoing T-Cell Redirection Therapy","RECRUITING","2027-04","2026-06","2026-06-22","2025-10-30","Yale University","OTHER",true,"This study evaluates the feasibility and safety of bridging radiation therapy, including a novel method for comparing the effectiveness of hypofractionated versus hyperfractionated radiation therapy in participants with relapsed\u002Frefractory diffuse large B-cell lymphoma (R\u002FR DLBCL) undergoing T-cell redirection therapies (CAR T-cell therapy or bispecific antibodies).","The purpose of this study is to assess the feasibility and safety of bridging radiation, including a novel method to study the relative effectiveness of hypo- vs. hyperfractionated therapy (i.e., once daily vs. twice daily treatment) in patients with R\u002FR DLBCL undergoing T-cell redirection therapies. This trial will serve as proof-of-concept, feasibility, and safety for a novel dual fractionation trial design, treating the same tumor with two fractionation schedules, paving the way for future radiotherapy trial designs and direct comparison of the efficacy of once vs. twice daily treatment. Correlative studies of immune exhaustion will evaluate the mechanistic underpinnings between radiotherapy and the immune environment. Finally, with the use of RefleXion BGRT, we will collect PET imaging data to provide the basis for this emerging method for administering bridging radiation in lymphoma.",[19],"Diffuse Large B-Cell Lymphoma",[21,22,23,24],"HyDEF","bridging radiation","once vs twice daily radiation","bulky disease lymphoma","INTERVENTIONAL","TREATMENT",[28],"NA",{"count":30,"type":31},10,"ESTIMATED",[33],{"type":14,"name":34,"description":35,"armGroupLabels":36},"Bridging Radiation Therapy","Study seeks to compare the hypofractionated radiation therapy with hyperfractionated treatment within the same tumor. Each participant will be serving as their own control; half their tumor will receive once daily hypofractionated (QD) bridging radiotherapy, and the other half of their tumor will receive twice daily hyperfractionated (BID) bridging radiotherapy. Either schedule is considered standard of care and this study aims to determine which schedule may prove superior between the two standards.",[37],"Dual Hyperfractionated Radiation Therapy",[39,43,47,51],{"measure":40,"description":41,"timeFrame":42},"Feasibility Assessment of Bridging Radiation Therapy","Feasibility will be assessed by the proportion of enrolled participants who are successfully treated according to the proposed bridging radiation therapy schema.","Approximately one year",{"measure":44,"description":45,"timeFrame":46},"Safety analysis of Bridging Radiation Therapy","Safety will be assessed by analyzing the incidence of severe (grade ≥ 3) acute toxicities. The therapy will be considered safe if fewer than 30% of study participants receiving dual fractionated radiation therapy experience these toxicities.","Throughout the study, approximately two years",{"measure":48,"description":49,"timeFrame":50},"Dynamics of Circulating Tumor DNA (ctDNA) as a Marker of Minimal Residual Disease","Changes in serum ctDNA levels will be measured at baseline and after radiation therapy (RT) to characterize ctDNA dynamics and assess minimal residual disease. Comparisons will focus on quantitative shifts in ctDNA burden in relation to treatment response.","Baseline (0-7 days prior to radiation therapy) to post-radiation therapy (prior to initiation of lymphodepleting chemotherapy)",{"measure":52,"description":53,"timeFrame":54},"Biomarkers of Hypoxia and Immune Exhaustion in Relation to Treatment Response","Serum biomarkers associated with tumor hypoxia and immune exhaustion will be evaluated at baseline and after radiation therapy (RT). Changes in these biomarkers will be compared to characterize biological responses to treatment and their relationship to clinical outcomes.","Baseline (0-7 days prior to radiation therapy) to post-radiation therapy (prior to initiation of lymphodepleting chemotherapy).",[],"ALL","18 Years",null,false,{"inclusion":61,"exclusion":62,"raw_text":63},[],[],"Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study.\n3. Adult aged 18 years or older.\n4. Histologically confirmed diagnosis of R\u002FR DLBCL with plan for CAR T or BsAb therapy at Yale New Haven Hospital.\n5. ECOG performance status 0 to 3.\n6. Ability to present for once or twice daily (M-F) fractionated radiation therapy, without contraindications for radiotherapy as determined by the treating radiation oncologist.\n7. Women of childbearing potential must have a negative serum or urine pregnancy test at screening and at time of radiation treatment planning, per standard of care and departmental standard operating procedure. Participants must agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through safety follow-up. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participants and their understanding confirmed.\n\nExclusion Criteria:\n\nParticipants who meet any of the following criteria will be disqualified from entering the study:\n\n1. Participants who are pregnant or currently breastfeeding.\n\n   a. Females who have undergone surgical sterilization or who have been postmenopausal for at least 12 months are not considered to be of childbearing potential.\n2. Participants with history of prior radiation exposure for research purposes within the past year, such that participation in this study would place them over the FDA limits for annual radiation exposure.\n3. Participants who are unable to safely receive FDG PET tracer.\n4. Any condition that would, in the investigator's judgment, interfere with full participation in the study and attending required study visits (if outpatient); pose a significant risk to the participant; or interfere with interpretation of study data.\n5. Participants who would not be anticipated to derive any clinical benefit from bridging radiotherapy, are unable to participate in twice daily radiotherapy, or have clinical contraindications to radiation therapy per treating investigator.",[65,66],"ADULT","OLDER_ADULT",[68],{"facility":13,"status":8,"city":69,"state":70,"zip":71,"country":72,"contacts":73,"geoPoint":82},"New Haven","Connecticut","06510","United States",[74,79],{"name":75,"role":76,"phone":77,"email":78},"Patricia Brand","CONTACT","203-785-4095","patricia.brand@yale.edu",{"name":80,"role":81},"Timothy Robinson, MD PhD","PRINCIPAL_INVESTIGATOR",{"lat":83,"lon":84},41.30815,-72.92816,[86],{"name":87,"role":76,"phone":88,"email":89},"Stephanie Ladd","203-785-5702","ycciprojectmanagement@yale.edu",[91],{"name":92,"affiliation":13,"role":81},"Timothy J Robinson, MD PhD",[],[],{"nct_id":4,"conditions":96,"biomarkers":97},[19],[],{"nct_id":4,"found":15,"summary":99,"prompt_version":109},{"design":100,"status":101,"heading":102,"summary":103,"follow_up":104,"word_count":105,"commitments":106,"compensation":107,"drugs_mentioned":108},"This is an interventional study with a planned enrollment of 10 participants. Each participant will serve as their own control, with different parts of their tumor receiving different radiation schedules.","completed","Bridging Radiation Therapy for Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma","This study is looking at a new way to give radiation therapy to people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to previous treatment (relapsed\u002Frefractory or R\u002FR DLBCL). It's for patients who are planning to receive CAR T-cell therapy or bispecific antibodies (BsAb), which are treatments that help your immune system fight cancer. The study will compare two ways of giving radiation – once a day (hypofractionated) versus twice a day (hyperfractionated) – to different parts of the same tumor. The main goals are to see if this type of radiation is possible to give and safe, and to track changes in circulating tumor DNA (ctDNA) to understand how well the treatment is working. You can join if you are 18 or older with R\u002FR DLBCL and are planning for CAR T or BsAb therapy at Yale New Haven Hospital. This study is currently recruiting about 10 participants.","Safety will be monitored throughout the study, for approximately two years. Feasibility will be assessed at approximately one year.",154,"Not specified in the trial record.","Not stated in the trial record.",[],"v2"]